- $525.25m
- $513.94m
- $0.04m
Entera Bio Ltd expected to post a loss of 8 cents a share - Earnings Preview
OPKO and Entera partner to develop obesity pill
Entera Bio Ltd expected to post a loss of 8 cents a share - Earnings Preview
Entera Bio Ltd expected to post a loss of 8 cents a share - Earnings Preview
Entera Bio Ltd expected to post a loss of 8 cents a share - Earnings Preview
Entera Bio Ltd expected to post a loss of 5 cents a share - Earnings Preview
Brief: Entera Bio And Opko Health Provide Update On Pk/Pd Results Of Oral Oxyntomodulin (Glp-1/Glucagon) Peptide Tablet Candidate For Obesity And Metabolic Disorders
Entera Bio Ltd reports results for the quarter ended in June - Earnings Summary
Entera Bio Ltd expected to post a loss of 6 cents a share - Earnings Preview
Entera Bio Ltd reports results for the quarter ended in March - Earnings Summary
Entera Bio Ltd expected to post a loss of 6 cents a share - Earnings Preview
Brief: Entera Bio Announces Full Year 2023 Financial Results
Brief: Entera Bio Says Co Regained Compliance With Nasdaq Minimum Bid Price Requirement
Brief: Entera Bio Files For Offering Of Up To 16.5 Million Shares By The Selling Shareholders - SEC Filing
Brief: Interim Results From Ongoing Clinical Study Confirm Eb613 Optimized Profile For Osteoporosis Treatment And Potential For Entera’S Next Generation Oral Peptide Platform
Entera Bio Ltd reports results for the quarter ended in June - Earnings Summary
Entera Bio Ltd expected to post a loss of 7 cents a share - Earnings Preview
Entera Bio Ltd expected to post a loss of 7 cents a share - Earnings Preview
Brief: Entera Bio Says On June 29, Co Got Notice From Nasdaq Stating That Co's Ordinary Shares Fail To Comply With $1.00 Minimum Bid Price Requirement